Biopharma companies are increasingly considering final production costs during early-stage process development. Furthermore, the most advanced companies have a razor-like focus on product quality and consider this early on in development. This ensures the best candidate is progressed into the clinic and costly failures are avoided.
Just - Evotec Biologics is helping partners with candidate antibodies, Fc-fusions, and bispecifics achieve the highest product quality with Cost of Goods Manufactured (COGM) of below $50/g by combining its brand new J.CHO High Expression System with its unique continuous manufacturing platform. This extraordinary productivity represents a 75% reduction in industry standard COGM and is driven by the exceptionally high antibody titers of over 4g/L/day in perfusion that our platform has been demonstrated to deliver. This performance is equivalent to a titer of approximately 30 g/L in fed-batch mode.
Watch our on-demand webinar, "A High Productivity CHO Expression System for the Continuous Manufacturing of Antibodies", for insights into our J.CHOTM High Expression System.
Meet the Speaker
Sherman Ku
Director of Cell Line Development, Just - Evotec Biologics
Sherman Ku received his PhD in molecular biology from The Scripps Research Institute after developing an iPSC-based disease model used for investigating the trinucleotide repeat expansion disease mechanism for Friedreich's ataxia. Afterwards, he continued on to the Allen Institute for Brain Science where he studied human brain development using engineered reporter iPSC lines, in vitro cortical neuronal differentiation, and various single-cell RNAseq-based viral lineage tracing techniques. Since joining Just-Evotec Biologics in 2016, Sherman has focused primarily on engineering CHO host cell lines with novel or improved functionality for biotherapeutic manufacturing.
If the webinar has not loaded above, please click the link here.
